USD/BRL continues its steady decline toward long-term support levels near 5.2500, with upcoming U.S. shutdown vote likely to trigger short-term volatility.
Excellent profit margins, understated future earnings potential, and winning the bidding war for Metsera have injected bullishness. Should you buy Pfizer following the Metsera deal?